Ascenion’s portfolio company APTA Therapeutics has acquired the rights to Berlin Cures' rovunaptabin drug. After top line results from its Phase II trial failed to demonstrate the efficacy of the DNA aptamer, a new study at Erlangen University Hospital is now showing positive results.

Ascenion’s partner institute Charité – Universitätsmedizin Berlin and NeoPredics AG have entered into a licence agreement for the use of the innovative PreFree technology. The main goal is the early prediction of the risk prediction of pre-eclampsia.

The Hamburg-based start-up TimeTeller is delighted to announce a strategic investment from capacura GmbH. The company is convinced that TimeTeller’s technology has the potential to fundamentally change medical care.

The amount of documentation required in hospitals is enormous, yet much of this data remains unused or is only accessible to individual departments. dotbase medical GmbH wants to change this: its platform structures clinical data centrally and enables comprehensive use.

Which market am I targeting with my business idea? Who are my potential customers? And who are my competitors? The answers to these questions help scientists make insight-driven strategic decisions.

Ascenion's new portfolio company RareLink is pursuing the important goal of enabling personalized therapy management for myasthenia gravis through telemonitoring with its ‘MyaLink’ platform. The rare neurological autoimmune disease causes muscle weakness.

"We ensure that innovation finds its way into society. This has become a profession in the academic world."
Dr Christian A. Stein, General Manager of Ascenion GmbH, in the new promotional film of TransferAllianz

How can public research organisations (PROs) better support the creation of successful spin-offs – and do so faster? A new report by the National Associations Advisory Committee (NAAC) of ASTP offers valuable insights into this question.

HepaRegeniX GmbH, a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, recently announced the second closing and completion of a EUR 21.5 million financing round with the addition of Wellington Partners to its investor syndicate.

"We are trend agnostics – we deliberately take a countercyclical approach"

How do I write a business plan? What funding is available for my project? What else do I need to consider before and while founding a start-up? Scientists can find the answers to these and many more questions in Ascenion’s new digital Roadmap.

How standardised benchmarks can make start-ups in the life sciences sector more efficient and transparent

A record number of over 320 innovators from the international life-science community gathered in Munich for the 17th BioVaria, Europe’s premier event for showcasing commercially attractive inventions and start-ups.

Ascenion’s portfolio company Aptila Biotech has launched DIA-NN 2.0, an AI-powered software that simplifies and enhances proteomics data analysis. The commercial version of DIA-NN 2.0 is now available, meeting strong industry demand.

At the end of January, 27 technology transfer experts met at Ascenion to share their experiences and discuss key issues relating to spin-offs, the design of basic agreements and software-based inventions.

Ankara, Turkey

Cologne, Germany

Munich, Germany

Kiel, Germany